Pancreatic cancer clinical trials near Edmonton

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

Recruiting now4 sites

Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the…

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Recruiting nowPhase 1/224 sites

BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to norm…

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Recruiting nowPhase 3322 sites

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care o…

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Recruiting nowPhase 21 site

A single-arm, interventional study combining Immunotherapy and propranolol with/without chemotherapy and propranolol 1. Pancreatic Cancer Durvalumab will be administered once every 4 weeks, in combination with gemcitabine + nab-paclitaxel …

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting nowPhase 285 sites

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carci…

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Recruiting nowPhase 235 sites

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…

18F-DOPA II - PET Imaging Optimization

Recruiting nowPhase 31 site

A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2. Pediatric patient…

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Recruiting nowPhase 1/247 sites

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fir…

Common questions

How do I find a pancreatic cancer clinical trial near me in Canada?

Use Beacon's free search: enter "pancreatic cancer", your age, and your location, and you'll see recruiting trials sorted by distance, each explained in plain language — including sites just across the US border. Beacon searches the full official registry and never requires an account.

Does joining a clinical trial cost money?

The study treatment and study-related tests are usually provided at no cost, and some trials help with travel. In Canada, your provincial health coverage continues to apply to your routine care — always confirm details with the study team.

Can I leave a clinical trial after joining?

Yes. Participation is always voluntary, and you can leave a trial at any time, for any reason, without losing your normal medical care.

Do I qualify for these trials?

Every trial has its own eligibility criteria. Beacon translates each trial's criteria into a plain-language checklist you can review and bring to your doctor — only the study team can confirm whether you qualify.